These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 35120786)

  • 21. Concurrent plexiform ameloblastoma and COVID-19-associated mucormycosis of the maxilla.
    Ingle Y; Sarode SC; Sarode G; Ingle M; Ingle S
    Oral Oncol; 2022 Feb; 125():105712. PubMed ID: 35016140
    [No Abstract]   [Full Text] [Related]  

  • 22. Can low-dose radiation therapy reduce the risk of mucormycosis in COVID-19 patients?
    Sharma DN; Welsh J; Kumar R
    J Cancer Res Ther; 2021; 17(6):1294-1296. PubMed ID: 34916356
    [No Abstract]   [Full Text] [Related]  

  • 23. Mucormycosis: An unanticipated progeny of COVID-19.
    Shrestha GS; Bhandari S; Lamsal R; Gurung U
    JNMA J Nepal Med Assoc; 2021 Sep; 59(241):965-967. PubMed ID: 35199723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intestinal mucormycosis in a patient with COVID-19: A case report.
    Paliwal P; Rahar S; Sharma A; Gupta D; Ahuja A; Chauhan DS
    Indian J Pathol Microbiol; 2022; 65(2):475-477. PubMed ID: 35435400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual hit - Magnetic resonance imaging in concomitant anterior and posterior ischemic optic neuropathy in a case of rhino-orbital mucormycosis and COVID-19.
    Kaushik KS; Acharya UV; Krupa L
    Indian J Ophthalmol; 2022 Jan; 70(1):300-301. PubMed ID: 34937262
    [No Abstract]   [Full Text] [Related]  

  • 26. Pulmonary Artery Pseudoaneurysm in COVID-19-Associated Pulmonary Mucormycosis: Case Series and Systematic Review of the Literature.
    Pruthi H; Muthu V; Bhujade H; Sharma A; Baloji A; Ratnakara RG; Bal A; Singh H; Sandhu MS; Negi S; Chakrabarti A; Singhal M
    Mycopathologia; 2022 Feb; 187(1):31-37. PubMed ID: 34936060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rhino-Orbital Cerebral Mucormycosis in Non-Diabetic Patients with COVID-19.
    Elhamamsy S; Bayer T; Al-Kaffas M; Hatahet S; Grover M; Samdhani S; Nanda A; Gravenstein S
    R I Med J (2013); 2021 Oct; 104(8):19-21. PubMed ID: 34582509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Black fungus immunosuppressive epidemic with Covid-19 associated mucormycosis (zygomycosis): a clinical and diagnostic perspective from India.
    Singh K; Kumar S; Shastri S; Sudershan A; Mansotra V
    Immunogenetics; 2022 Apr; 74(2):197-206. PubMed ID: 34596728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coronavirus disease (COVID-19) complicated by rhino-orbital-cerebral mucormycosis presenting with neurovascular thrombosis: a case report and review of literature.
    Ostovan VR; Rezapanah S; Behzadi Z; Hosseini L; Jahangiri R; Anbardar MH; Rostami M
    J Neurovirol; 2021 Aug; 27(4):644-649. PubMed ID: 34342852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [COVID-19 associated mucormycosis. A case in Argentina].
    Aparicio M; Tuculet B; Rivolier MG; Forte A; Vila A
    Medicina (B Aires); 2022; 82(2):304-307. PubMed ID: 35417397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rhinocerebral Mucormycosis in a COVID-19 Patient from Nepal: A Case Report.
    Kumar Gupta S; Jyotsana P; Singh A; Phuyal D; Allam P
    JNMA J Nepal Med Assoc; 2021 Jul; 59(239):703-705. PubMed ID: 34508493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19 and mucormycosis superinfection: the perfect storm.
    Al-Tawfiq JA; Alhumaid S; Alshukairi AN; Temsah MH; Barry M; Al Mutair A; Rabaan AA; Al-Omari A; Tirupathi R; AlQahtani M; AlBahrani S; Dhama K
    Infection; 2021 Oct; 49(5):833-853. PubMed ID: 34302291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-hospital prevalence of mucormycosis among coronavirus disease 2019 (COVID-19) patients and COVID-19 in mucormycosis: a systematic review and meta-analysis.
    Sinha A; Bhaskar SMM
    Int Forum Allergy Rhinol; 2022 Mar; 12(3):313-317. PubMed ID: 34633150
    [No Abstract]   [Full Text] [Related]  

  • 34. Mucormycosis and Covid-19 : Risk Factors, Clinical Presentation and Outcome in a Tertiary Care Centre in North India.
    A GA; Ashraf H; HaiderMehdi HS
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucormycosis in COVID-19 pandemic and its neurovascular spread.
    Pal P; Singh B; Singla S; Kaur R
    Eur Arch Otorhinolaryngol; 2022 Jun; 279(6):2965-2972. PubMed ID: 34637017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mucormycosis, conflicts and COVID-19: A deadly recipe for the fragile health system of Afghanistan.
    Essar MY; Khan H; Babar MS; Hasan MM; Rackimuthu S; Dos Santos Costa AC; Ahmad S; Nemat A
    Int J Health Plann Manage; 2022 Jan; 37(1):543-546. PubMed ID: 34333804
    [No Abstract]   [Full Text] [Related]  

  • 37. Commentary: Data and COVID-19-associated mucormycosis: Time to pause and reassess?
    Nair AG
    Indian J Ophthalmol; 2022 Mar; 70(3):1024-1025. PubMed ID: 35225565
    [No Abstract]   [Full Text] [Related]  

  • 38. COVID-19 and Mucormycosis in India a Study on Implicated Risk Factors.
    Deepak P; Rao MR; Mandadi K
    J Assoc Physicians India; 2022 May; 70(5):11-12. PubMed ID: 35598140
    [No Abstract]   [Full Text] [Related]  

  • 39. Mucormycosis in COVID-19 recovered patients.
    Kumar A
    J Med Virol; 2022 Apr; 94(4):1272-1273. PubMed ID: 34905224
    [No Abstract]   [Full Text] [Related]  

  • 40. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis.
    Pasero D; Sanna S; Liperi C; Piredda D; Branca GP; Casadio L; Simeo R; Buselli A; Rizzo D; Bussu F; Rubino S; Terragni P
    Infection; 2021 Oct; 49(5):1055-1060. PubMed ID: 33331988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.